Generated by AI
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.
Website675 Massachusetts Avenue
Cambridge, MA, 02139
United States
The latest articles about SPRO.
Summary of Sep 22's posts. Generated by AI.
Summary of Jun 18's posts. Generated by AI.
Summary of Jun 17's posts. Generated by AI.
Investors talking about SPRO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.